Synopsis
Synopsis
0
VMF
DRUG PRODUCT COMPOSITIONS
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. 4-(4-(3-(4-chloro-3-trifluoromethylphenyl)ureido)phenoxy)pyridine-2-carboxylic Acid Methyamide-4-methylbenzenesulfonate
2. Bay 43 9006
3. Bay 43-9006
4. Bay 439006
5. Bay 545 9085
6. Bay 545-9085
7. Bay 5459085
8. Bay 673472
9. Bay-545-9085
10. Bay-673472
11. Bay5459085
12. Nexavar
13. Sorafenib
14. Sorafenib N Oxide
15. Sorafenib N-oxide
1. 475207-59-1
2. Nexavar
3. Sorafenib Tosylate [usan]
4. Sorafenib (tosylate)
5. Sorafenib Tosilate
6. Bay 54-9085
7. 475207-59-1 (tosylate)
8. 4-(4-(3-(4-chloro-3-(trifluoromethyl)phenyl)ureido)phenoxy)-n-methylpicolinamide 4-methylbenzenesulfonate
9. Chebi:50928
10. 5t62q3b36j
11. Mfcd08235032
12. Bay-54-9085
13. Sorafenib Tosilate (jan)
14. Sorafenib (nexavar)
15. Sorafenib Tosylate (usan)
16. Nexavar(r)
17. Dsstox_cid_27817
18. Dsstox_rid_82581
19. Dsstox_gsid_47839
20. 1-(4-chloro-3-(trifluoromethyl)phenyl)-3-(4-((2-(methylcarbamoyl)pyridin-4-yl)oxy)phenyl)urea Mono(4-methylbenzenesulfonate)
21. 4-(4-(3-(4-chloro-3-(trifluoromethyl)phenyl)ureido)phenoxy)-n2-methylpyridine-2-carboxamide Mono (4-methylbenzenesulfonate)
22. 4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-n-methylpyridine-2-carboxamide;4-methylbenzenesulfonic Acid
23. Sorafenib Tosilate [jan]
24. Bay 43-9006 Tosylate
25. 4-(4-(3-(4-chloro-3-(trifluoromethyl)phenyl)ureido)phenoxy)-n-methylpicolinamide 4-methylbenzenesulfonate.
26. 4-[4-({[4-chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)phenoxy]-n-methylpyridine-2-carboxamide; 4-methylbenzene-1-sulfonic Acid
27. Cas-475207-59-1
28. Nsc-724772
29. Ncgc00167488-01
30. Unii-5t62q3b36j
31. Sr-00000000529
32. Orafenib Tosylate
33. Bay43-9006 Mono-p-tosylate
34. Bay 43-9006 Mono-p-tosylate
35. 4-(4-(((4-chloro-3-(trifluoromethyl)phenyl)carbamoyl)amino)phenoxy)-n-methylpyridine-2-carboxamide 4-methylbenzenesulfonate
36. 4-[4-({[4-chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)phenoxy]-n-methylpyridine-2-carboxamide 4-methylbenzenesulfonate
37. Nexavar (tn)
38. Nsc724772
39. Sorafenib - Nexavar
40. Sorafenib Tsoh Salt
41. Mls002415564
42. Sorafenib Tosylate [mi]
43. Chembl1200485
44. Dtxsid9047839
45. Sorafenib (bay-43-9006)
46. Hms2219e08
47. Hms3654i09
48. Sorafenib, P-toluenesulfonate Salt
49. Sorafenib Tosilate [mart.]
50. Sorafenib Tosilate [who-dd]
51. Sorafenib Tosylate [usp-rs]
52. Tox21_112489
53. Hy-10201a
54. S1040
55. Akos015924650
56. Akos027469919
57. Tox21_112489_1
58. Ac-6799
59. Ccg-208000
60. Cs-0164
61. Nd-0228
62. Sorafenib Tosylate [orange Book]
63. Ncgc00167488-08
64. Sorafenib Tosilate [ep Monograph]
65. 2-pyridinecarboxamide, 4-(4-((((4-chloro-3-(trifluoromethyl)phenyl)amino)carbonyl)amino)phenoxy)-n-methyl-, Mono(4-methylbenzenesulfonate)
66. Bs164414
67. Smr001339079
68. Sorafenib Tosylate [usp Monograph]
69. Sy012324
70. Bcp0726000112
71. Am20090612
72. Ft-0650737
73. Ft-0698449
74. Sw202562-3
75. Ec-000.2356
76. A25518
77. D06272
78. S-8502
79. 207s591
80. Q-201729
81. Sr-00000000529-5
82. 2,5-dioxo-1,4-cyclohexanedicarboxylicaciddimethylester
83. Q27122250
84. 4-(4-(3-(4-chloro-3-(trifluoromethyl)phenyl)ureido)phenoxy)-n-methylpicolinamide Tosylate
85. 2-pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-n-methyl-, 4-methylbenzenesulfonate (1:1)
86. 4-(4-(((4-chloro-3-(trifluoromethyl)phenyl)carbamoyl)amino)phenoxy)-n-methylpyridine-2-carboxamide 4-methylbenzenesulphonate
87. 4-(4-(3-(4-chloro-3-(trifluoromethyl)phenyl)ureido)phenoxy)-n-methylpicolinamide4-methylbenzenesulfonate
88. 4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-n-methyl-2-pyridinecarboxamide Tosylate
89. 4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-n-methylpyridine-2-carboxamide;hydron;4-methylbenzenesulfonate
90. 4-{4-[({[4-chloro-3-(trifluoromethyl)phenyl]amino}carbonyl)-amino]phenoxy}-n-methylpyridine-2-carboxamide Tosylate
91. 4-{4-[({[4-chloro-3-(trifluoromethyl)phenyl]amino}carbonyl)amino]phenoxy}-n -methylpyridine-2-carboxamide Tosylate
92. 4-{4-[({[4-chloro-3-(trifluoromethyl)phenyl]amino}carbonyl)amino]phenoxy}-n-methylpyridine-2-carboxamide Tosylate
93. 4-{4-[3-(4-chloro-3-trifluoromethyl-phenyl)-ureido]-phenoxy} -pyridine-2-carboxylic Acid Methylamide-4-methylbenzenesulfonate
94. 4-{4-[3-(4-cl-3-trifluoromethyl-phenyl)-ureido]-phenoxy}-pyridine-2-carboxylic Acid Methylamide 4-methylbenzenesulfonate
95. 4-methyl-3-((4-(3-pyridinyl)-2-pyrimidinyl)amino)-n-(5-(4-methyl-1h-imidazol-1-yl)-3-(trifluoromethyl)phenyl)benzamide Monomethanesulfonate
Molecular Weight | 637.0 g/mol |
---|---|
Molecular Formula | C28H24ClF3N4O6S |
Hydrogen Bond Donor Count | 4 |
Hydrogen Bond Acceptor Count | 10 |
Rotatable Bond Count | 6 |
Exact Mass | 636.1057179 g/mol |
Monoisotopic Mass | 636.1057179 g/mol |
Topological Polar Surface Area | 155 Ų |
Heavy Atom Count | 43 |
Formal Charge | 0 |
Complexity | 853 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 0 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 2 |
1 of 2 | |
---|---|
Drug Name | Nexavar |
PubMed Health | Sorafenib (By mouth) |
Drug Classes | Antineoplastic Agent |
Drug Label | NEXAVAR, a kinase inhibitor, is the tosylate salt of sorafenib. Sorafenib tosylate has the chemical name 4-(4-{3-[4-Chloro-3-(trifluoromethyl)phenyl]ureido}phenoxy)N2-methylpyridine-2-carboxamide 4-methylbenzenesulfonate and its structural formula is... |
Active Ingredient | Sorafenib tosylate |
Dosage Form | Tablet |
Route | Oral |
Strength | eq 200mg base |
Market Status | Prescription |
Company | Bayer Hlthcare |
2 of 2 | |
---|---|
Drug Name | Nexavar |
PubMed Health | Sorafenib (By mouth) |
Drug Classes | Antineoplastic Agent |
Drug Label | NEXAVAR, a kinase inhibitor, is the tosylate salt of sorafenib. Sorafenib tosylate has the chemical name 4-(4-{3-[4-Chloro-3-(trifluoromethyl)phenyl]ureido}phenoxy)N2-methylpyridine-2-carboxamide 4-methylbenzenesulfonate and its structural formula is... |
Active Ingredient | Sorafenib tosylate |
Dosage Form | Tablet |
Route | Oral |
Strength | eq 200mg base |
Market Status | Prescription |
Company | Bayer Hlthcare |
* Hepatocellular carcinoma:
Nexavar is indicated for the treatment of hepatocellular carcinoma.
* Renal cell carcinoma:
Nexavar is indicated for the treatment of patients with advanced renal cell carcinoma who have failed prior interferon-alpha or interleukin-2 based therapy or are considered unsuitable for such therapy.
* Differentiated thyroid carcinoma:
Nexavar is indicated for the treatment of patients with progressive, locally advanced or metastatic, differentiated (papillary/follicular/Hrthle cell) thyroid carcinoma, refractory to radioactive iodine.
Antineoplastic Agents
Substances that inhibit or prevent the proliferation of NEOPLASMS. (See all compounds classified as Antineoplastic Agents.)
Protein Kinase Inhibitors
Agents that inhibit PROTEIN KINASES. (See all compounds classified as Protein Kinase Inhibitors.)
L01EX02
Minakem delivers API, HPAPI, steroids & CDMO services for generics with FDA/GMP certification, regulatory know-how & proven success.
GDUFA
DMF Review : Reviewed
Rev. Date : 2018-07-27
Pay. Date : 2018-01-19
DMF Number : 32140
Submission : 2017-12-20
Status : Active
Type : II
LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.
Faran Shimi: Leading producer of high-quality APIs & alkaloid opiates, serving major pharmaceutical companies across the Middle East.
Granules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 37229
Submission : 2022-06-30
Status : Active
Type : II
NDC Package Code : 62207-982
Start Marketing Date : 2023-08-01
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
GDUFA
DMF Review : Reviewed
Rev. Date : 2015-09-18
Pay. Date : 2015-06-12
DMF Number : 29340
Submission : 2015-06-30
Status : Active
Type : II
GDUFA
DMF Review : Reviewed
Rev. Date : 2016-04-01
Pay. Date : 2016-02-01
DMF Number : 30234
Submission : 2016-02-23
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 26460
Submission : 2012-09-18
Status : Inactive
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 27793
Submission : 2013-11-20
Status : Inactive
Type : II
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
Related Excipient Companies
Excipients by Applications
Global Sales Information
Market Place
Patents & EXCLUSIVITIES
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
LOOKING FOR A SUPPLIER?